Video

Role of Second Generation FLT3 Inhibitors in AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP, FHOPA

Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.

Related Videos
Related Content
HOPA 2025: The Promise and Pitfalls of ctDNA Testing in Oncology
April 11th 2025

HOPA 2025: The Promise and Pitfalls of ctDNA Testing in Oncology

Alana Hippensteele, Lead Editor
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Visualization of bispecific antibodies | Image Credit: © huenstructurebio.com - stock.adobe.com
April 7th 2025

Emerging Bispecific T-Cell Engagers in Myeloma: Promises and Hurdles

Ashley Chen, PharmD, BCOP Chloe Siu, PharmD, BCPS, BCOP
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

Multiple myeloma cells | Image Credit: © kamonrat - stock.adobe.com
April 4th 2025

Caveolin-1 May Be A Promising Therapeutic Target For Multiple Myeloma, Study Finds

Alexandra Gerlach, Associate Editor
Chemical structure of MDM2 protein binding p53 | Image Credit: © Juan Gärtner - stock.adobe.com
April 3rd 2025

Siremadlin Demonstrates Efficacy, Safety in Treatment of Patients With TP53 Wild-Type Chronic Lymphocytic Leukemia

Alexandra Gerlach, Associate Editor